Patent Assignment
Reel/Frame 063119/0087
Assignee Address Correction
Recorded: 2023-03-20
Pages: 29
Assignor
PFIZER INC.
Executed: 2023-03-07
Assignee
PFIZER INC.
66 HUDSON BOULEVARD EAST, LEGAL PATENT DEPT, CHIEF IP COUNSEL, NEW YORK, NEW YORK, 10001-2192
Covered Properties
(478)
Pyrrolo[2,3-D]Pyrimidine Compounds
Patent:
41,783 →
Application:
12/577,790 →
Tropane Derivatives Useful in Therapy
Chiral Salt Resolution
Aminoheteroaryl Compounds as Protein Kinase Inhibitors
Aminoheteroaryl Compounds as Protein Kinase Inhibitors
Multiparticulate Crystalline Drug Compositions Having Controlled Release Profiles
Method of Making Pharmaceutical Multiparticulates
Azithromycin Dosage Forms with Reduced Side Effects
Bicyclic [3.1.0] Derivatives as Glycine Transporter Inhibitors
Cpg Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity
CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity
CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity
Enantiomerically Pure Aminoheteroaryl Compounds as Protein Kinase Inhibitors
Enantiomerically Pure Aminoheteroaryl Compounds as Protein Kinase Inhibitors
Pyrrolo[2,3-D]Pyrimidine Derivatives; Their Intermediates and Synthesis
Pyrrolo[2,3-D]Pyrimidine Derivatives: Their Intermediates and Synthesis
Bicyclic [3.1.0] Heteroaryl Amides as Type 1 Glycine Transport Inhibitors
Fused Phenyl Amido Heterocyclic Compounds
Fused Phenyl Amido Heterocyclic Compounds
Method of Treating Abnormal Cell Growth
Polymorphs of a C-Met/Hgfr Inhibitor
Crystalline Forms of 6-[2-(Methylcarbamoyl)Phenylsulfanyl]-3-E-[2-(Pyridin-2-Yl)Ethenyl]Indazole Suitable for the Treatment of Abnormal Cell Growth in Mammals
Benzimidazole Derivatives
Benzimidazole Derivatives
Stable Liquid Antibody Formulation
Pyrrolo[2,3-D]Pyrimidine Compounds
Treatment of Chronic Prostatitis
Dioxa-Bicyclo[3.2.1]Octane-2,3,4-Triol Derivatives
2,3-Dihydro-1H-Inden-1-Yl-2,7-Diazaspiro[3.5] Nonane Derivatives
4-1BB Binding Molecules
4-1BB Binding Molecules
Method of Producing 4-1BB Binding Molecules and Associated Nucleic Acids
4-1BB Binding Molecules
Benzofuranyl Derivatives
Benzofuranyl Derivatives
Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
Dioxa-Bicyclo[3.2.1]Octane-2,3,4-Triol Derivatives
Dioxa-Bicyclo[3.2.1]Octane-2,3,4-Triol Derivatives
Dioxa-Bicyclo[3.2.1]Octane-2,3,4-Triol Derivatives
Dioxa-Bicyclo[3.2.1]Octane-2,3,4-Triol Derivatives
N1-Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
N1-Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
N1-Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
N1-Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
Indole and Indazole Compounds that Activate AMPK
Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
Stable Formulations for Lyophilizing Therapeutic Particles
Stable Formulations for Lyophilizing Therapeutic Particles
Stable Formulations for Lyophilizing Therapeutic Particles
Stable Formulations for Lyophilizing Therapeutic Particles
Stable Formulations for Lyophilizing Therapeutic Particles
Stable Formulations for Lyophilizing Therapeutic Particles
Stable Formulations for Lyophilizing Therapeutic Particles
Stable Formulations for Lyophilizing Therapeutic Particles
Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Temperature or High Molecular Weight Copolymers
Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Termperature or High Molecular Weight Copolymers
Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Temperature or High Molecular Weight Copolymers
Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Temperature or High Molecular Weight Copolymers
Process for Preparing Therapeutic Nanoparticles
Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same
Therapeutic Nanoparticles Comprising a Protonatable Nitrogen Therapeutic Agent and Methods of Making and Using Same
Targeted Therapeutic Nanoparticles and Methods of Making and Using Same
Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making And Using Same
Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making And Using Same
Application:
17/178,846 →
Publication:
US US20210259982A1
Methods for the Preparation of Targeting Agent Functionalized Diblock Copolymers for Use in Fabrication of Therapeutic Targeted Nanoparticles
Addition of Iron to Improve Cell Culture
Application:
14/352,740 →
Publication:
US US20140322758A1
Novel Bicyclic Pyridinones
Novel Bicyclic Pyridinones
N1/N2-Lactam Acetyl-Coa Carboxylase Inhibitors
N1/N2-Lactam Acetyl-Coa Carboxylase Inhibitors
N1/N2-Lactam Acetyl-Coa Carboxylase Inhibitors
Tandem Purification of Proteins
Imidazo[5,1-F][1,2,4]Triazines for the Treatment of Neurological Disorders
Beneficial Effects of Combination Therapy on Cholesterol
Glucagon Receptor Modulators
Substituted Acetyl-Coa Carboxylase Inhibitors
Quinolinyl Glucagon Receptor Modulators
Engineered Antibody Constant Regions for Site-Specific Conjugation and Methods and Uses Therefor
2-Thiopyrimidinones
Cytotoxic Peptides and Antibody Drug Conjugates Thereof
Cytotoxic Peptides and Antibody Drug Conjugates Thereof
Cytotoxic Peptides and Antibody Drug Conjugates Thereof
Macrocyclic Derivatives for the Treatment of Diseases
Macrocyclic Derivatives for the Treatment of Diseases
Neisseria Meningitidis Compositions and Methods Thereof
Neisseria Meningitidis Compositions and Methods Thereof
Neisseria Meningitidis Composition and Methods Thereof
Neisseria Meningitidis Composition and Methods Thereof
Neisseria Meningitidis Composition and Methods Thereof
Neisseria Meningitidis Composition and Methods Thereof
Neisseria Meningitidis Composition and Methods Thereof
Novel Selective Androgen Receptor Modulators
Indole and Indazole Compounds That Activate Ampk
Diacylglycerol Acyltransferase 2 Inhibitors
Use of Ghrelin Receptor Inverse Agonists or Antagonists for Treating Sleep Disorders
Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
Streptococcus Pneumoniae Capsular Polysaccharides and Conjugates Thereof
Streptococcus Pneumoniae Capsular Polysaccharides and Conjugates Thereof
Streptococcus Pneumoniae Capsular Polysaccharides and Conjugates Thereof
Glycoconjugation Processes and Compositions
Glycoconjugation Processes and Compositions
Glycoconjugation Processes and Compositions
Glycoconjugation Processes and Compositions
Glycoconjugation Processes and Compositions
SUBSTITUTED PYRIDO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEURODEGENERATIVE AND NEUROLOGICAL DISORDERS
SUBSTITUTED PYRIDO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEURODEGENERATIVE AND NEUROLOGICAL DIORDERS
SUBSTITUTED PYRIDO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEURODEGENERATIVE AND NEUROLOGICAL DISORDERS
Pyrrolo[2,3-D]Pyrimidine Derivatives
Pyrrolo[2,3-D]Pyrimidine Derivatives
Pyrrolo[2,3-D]Pyrimidine Derivatives
Engineered Monomeric Antibody Fragments
Anti-CXCR4 Antibodies and Antibody-Drug Conjugates
Anti-CXCR4 Antibodies and Antibody-Drug Conjugates
Anti-CXCR4 Antibodies and Antibody-Drug Conjugates
Anti-CXCR4 Antibodies and Antibody-Drug Conjugates
Bruton's Tyrosine Kinase Inhibitors
Bruton's Tyrosine Kinase Inhibitors
Bruton's Tyrosine Kinase Inhibitors
Application:
17/025,026 →
Publication:
US US20210002251A1
Compositions and Methods Relating to a Mutant Clostridium Difficile Toxin
Compositions and Methods Relating to a Mutant Clostridium Difficile Toxin
Compositions and Methods Relating to a Mutant Clostridium Difficile Toxin
Compositions and Methods Relating to a Mutant Clostridium Difficile Toxin
Tofacitinib Oral Sustained Release Dosage Forms
Tofacitinib Oral Sustained Release Dosage Forms
Tofacitinib Oral Sustained Release Dosage Forms
Tofacitinib Oral Sustained Release Dosage Forms
Application:
17/580,991 →
Publication:
US US20220142927A1
Glycoconjugation Process
Glycoconjugation Process
Glycoconjugation Process
Glycoconjugation Process
Bispecific Antibodies
Aryl and Heteroaryl Fused Lactams
Aryl and Heteroaryl Fused Lactams
Solid Forms of a Selective CDK4/6 Inhibitor
Immunogenic Fusion Polypeptides
Bicyclic-Fused Heteroaryl or Aryl Compounds
Bicyclic-Fused Heteroaryl or Aryl Compounds
Bicyclic-Fused Heteroaryl or Aryl Compounds
Bicyclic-Fused Heteroaryl or Aryl Compounds
Bicyclic-Fused Heteroaryl or Aryl Compounds
Streptococcus Pneumoniae Capsular Polysaccharides and Conjugates Thereof
Application:
17/125,555 →
Publication:
US US20210121555A1
Aminopyrimidinyl Compounds
Aminopyrimidinyl Compounds
Application:
17/396,094 →
Publication:
US US20210377495A1
Pyrrolo[2,3-D]Pyrimidinyl, Pyrrolo[2,3-B]Pyrazinyl and Pyr-Rolo[2,3-D]Pyridinyl Acrylamides
Pyrrolo[2,3-D]Pyrimidinyl, Pyrrolo[2,3-B]Pyrazinyl and Pyrrolo[2,3-D]Pyridinyl Acrylamides
Pyrrolo[2,3-D]Pyrimidinyl, Pyrrolo[2,3-B]Pyrazinyl and Pyrrolo[2,3-D]Pyridinyl Acrylamides
Pyrazolopyridines and Pyrazolopyrimidines
Pyrazolopyridines and Pyrazolopyrimidines
Purine Derivatives
Solid Forms of a Macrocyclic Kinase Inhibitor
Cycloalkyl-Linked Diheterocycle Derivatives
Cycloalkyl-Linked Diheterocycle Derivatives
Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof
Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof
Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof
Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof
Bifunctional Cytotoxic Agents
Bifunctional Cytotoxic Agents
Neisseria Meningitidis Compositions and Methods Thereof
Neisseria Meningitidis Compositions and Methods Thereof
Neisseria Meningitidis Compositions and Methods Thereof
Fxa Variant Compositions
Methods for Purifying Fxa Variant Proteins
Intermediates and Methods for Synthesizing Calicheamicin Derivatives
Intermediates and Methods for Synthesizing Calicheamicin Derivatives
Substituted-6,8-Dioxabicyclo[3.2.1]Octane-2,3-Diol Compounds as Targeting Agents of Asgpr
Substituted-6,8-Dioxabicyclo[3.2.1]Octane-2,3-Diol Compounds as Targeting Agents of Asgpr
Substituted-6,8-Dioxabicyclo[3.2.1]Octane-2,3-Diol Compounds as Targeting Agents of Asgpr
Substituted-6,8-Dioxabicyclo[3.2.1]Octane-2,3-Diol Compounds as Targeting Agents of Asgpr
Substituted-6,8-Dioxabicyclo[3.2.1]Octane-2,3-Diol Compounds as Targeting Agents of Asgpr
Pyrrolo[2,3-D]Pyrimidine Derivatives
Diacylglycerol Acyltransferase 2 Inhibitors
Diacylglycerol Acyltransferase 2 Inhibitors
Diacylglycerol Acyltransferase 2 Inhibitors
Immunogenic Glycoprotein Conjugates
Immunogenic Glycoprotein Conjugates
Site Specific HER2 Antibody Drug Conjugates
Immunogenic Compositions for Use in Pneumococcal Vaccines
Immunogenic Compositions for Use in Pneumococcal Vaccines
Immunogenic Compositions for Use in Pneumococcal Vaccines
Application:
17/463,691 →
Publication:
US US20210393764A1
Tissue Factor Pathway Inhibitor Antibodies and Uses Thereof
Tissue Factor Pathway Inhibitor Antibodies and Uses Thereof
Tissue Factor Pathway Inhibitor Antibodies and Uses Thereof
MUTEINS OF CLOTTING FACTOR Vlll
Method of Cell Culture
Method of Cell Culture
Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using the Same
Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using the Same
Crystalline Form of 6-[(4R)-4-Methyl-1,2-Dioxido-1,2,6-Thiadiazinan-2-Yl]Isoquinoline-1-Carbonitrile
Substituted Dihydroisoquinolinone Compounds
Substituted Dihydroisoquinolinone Compounds
Axl Inhibitors
Methods of Use and Combinations
Fluoro-Pyridinone Phosphates And Boronates Useful As Antibacterial Agents
Crystalline Solid Forms of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole
Pyrrolo[2,3-D]Pyrimidinyl, Pyrrolo[2,3-B]Pyrazinyl, Pyrrolo[2,3-B]Pyridinyl Acrylamides and Epoxides Thereof
Substituted Nucleoside Derivatives Useful as Anticancer Agents
2-Thiopyrimidinones
Stable Aqueous Anti-Vascular Endothelial Growth Factor (Vegf) Antibody Formulation
Stable Aqueous Antibody Formulation
Application:
17/142,353 →
Publication:
US US20210128729A1
Novel Cyclopropabenzofuranyl Pyridopyrazinediones
Neisseria Meningitidis Compositions and Methods Thereof
Neisseria Meningitidis Compositions and Methods Thereof
Application:
17/114,802 →
Publication:
US US20210085773A1
Bifunctional Cytotoxic Agents Containing the Cti Pharmacophore
Bifunctional Cytotoxic Agents Containing the Cti Pharmacophore
Therapeutic Antibodies and Their Uses
Therapeutic Antibodies and Their Uses
Therapeutic Antibodies and Their Uses
Therapeutic Antibodies and Their Uses
Therapeutic Antibodies and Their Uses
Method Of Preparing A Therapeutic Protein Formulation And Antibody Formulation Produced By Such A Method
Application:
15/761,777 →
Publication:
US US20230134160A1
Crystalline Forms of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate
Crystalline Forms of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate
Crystalline Forms of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate
Crystalline Forms of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate
Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens, Kits Comprising the Same and Uses Thereof
Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens, Kits Comprising the Same and Uses Thereof
Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens, Kits Comprising the Same and Uses Thereof
Application:
17/241,603 →
Publication:
US US20210260177A1
Group B Streptococcus Polysaccharide-Protein Conjugates, Methods for Producing Conjugates, Immunogenic Compositions Comprising Conjugates, and Uses Thereof
Group B Streptococcus Polysaccharide-Protein Conjugates, Methods for Producing Conjugates, Immunogenic Compositions Comprising Conjugates, and Uses Thereof
Group B Streptococcus Polysaccharide-Protein Conjugates, Methods for Producing Conjugates, Immunogenic Compositions Comprising Conjugates, and Uses Thereof
Application:
18/060,779 →
Publication:
US US20230346903A1
Humanized Antibodies
Humanized Antibodies
RSV F Protein Mutants
RSV F Protein Mutants
RSV F Protein Mutants
RSV F Protein Mutants
Application:
17/060,944 →
Publication:
US US20210023200A1
Novel Heterocyclic Compounds as Inhibitors of Vanin-1 Enzyme
Antibodies Having Conditional Affinity and Methods of Use Thereof
Application:
16/500,970 →
Publication:
US US20230192839A1
Solid Dosage Forms of Palbociclib
Solid Dosage Forms of Palbociclib
Application:
17/349,916 →
Publication:
US US20210315900A1
Cell Culture Process
Application:
16/088,676 →
Publication:
US US20190112572A1
Bicyclic-Fused Heteroaryl or Aryl Compounds as IRAK4 Modulators
Bicyclic-Fused Heteroaryl or Aryl Compounds as IRAK4 Modulators
Immunogenic Compositions for Use in Pneumococcal Vaccines
Immunogenic Compositions for Use in Pneumococcal Vaccines
Application:
17/000,590 →
Publication:
US US20200405837A1
1,1,1-Trifluoro-3-Hydroxypropan-2-Yl Carbamate Derivatives and 1,1,1-Trifluoro-4-Hydroxybutan-2-Yl Carbamate Derivatives as Magl Inhibitors
1,1,1-Trifluoro-3-Hydroxypropan-2-Yl Carbamate Derivatives and 1,1,1-Trifluoro-4-Hydroxybutan-2-Yl Carbamate Derivatives as Magl Inhibitors
1,1,1-Trifluoro-3-Hydroxypropan-2-Yl Carbamate Derivatives and 1,1,1-Trifluoro-4-Hydroxybutan-2-Yl Carbamate Derivatives as Magl Inhibitors
Crystalline Form of Lorlatinib Free Base
Crystalline Form of Lorlatinib Free Base
Cells Having Reduced BCAT1
Cells and Method of Cell Culture
Anti-Il-33 Antibodies, Compositions, Methods and Uses Thereof
Media and Fermentation Methods for Producing Polysaccharides in Bacterial Cell Culture
Media and Fermentation Methods for Producing Polysaccharides in Bacterial Cell Culture
Application:
17/170,036 →
Publication:
US US20210180008A1
Novel Pyrimidine Carboxamides as Inhibitors of Vanin-1 Enzyme
Substituted 3-Azabicyclo[3.1.0]Hexanes as Ketohexokinase Inhibitors
Substituted 3-Azabicyclo[3.1.0]Hexanes as Ketohexokinase Inhibitors
Substituted 3-Azabicyclo[3.1.0]Hexanes as Ketohexokinase Inhibitors
Substituted 3-Azabicyclo[3.1.0]Hexanes as Ketohexokinase Inhibitors
Substituted 3-Azabicyclo[3.1.0]Hexanes as Ketohexokinase Inhibitors
Pyrazolo[1,5-A]Pyrazin-4-Yl and Related Derivatives
Crystalline Forms of Lorlatinib Maleate
Crystalline Forms of Lorlatinib Maleate
Human Cytomegalovirus Gb Polypeptide
Antibodies and Antibody Fragments for Site-Specific Conjugation
Application:
15/356,953 →
Publication:
US US20170216452A1
Antibodies and Antibody Fragments for Site-Specific Conjugation
Application:
16/688,173 →
Publication:
US US20200069764A1
CDK2/4/6 Inhibitors
CDK2/4/6 Inhibitors
CDK2/4/6 Inhibitors
CDK2/4/6 Inhibitors
Application:
17/841,138 →
Publication:
US US20220324872A1
Diacylglycerol Acyl Transferase 2 Inhibitors
Diacylglycerol Acyl Transferase 2 Inhibitors
Diacylglycerol Acyl Transferase 2 Inhibitors
Substituted Carbonucleoside Derivatives Useful as Anticancer Agents
Substituted Carbonucleoside Derivatives Useful as Anticancer Agents
Immunogenic Compositions for Use in Pneumococcal Vaccines
Immunogenic Compositions for Use in Pneumococcal Vaccines
Anti-Proliferative Agents for Treating Pah
Anti-Proliferative Agents for Treating Pah
Immunogenic Compositions and Uses Thereof
Immunogenic Compositions and Uses Thereof
Immunogenic Compositions and Uses Thereof
GLP-1 Receptor Agonists and Uses Thereof
Glp-1 Receptor Agonists and Uses Thereof
Glp-1 Receptor Agonists and Uses Thereof
Glp-1 Receptor Agonists and Uses Thereof
Glp-1 Receptor Agonists and Uses Thereof
1,1,1-Trifluoro-3-Hydroxypropan-2-Yl Carbamate Derivatives as Magl Inhibitors
1,1,1-Trifluoro-3-Hydroxypropan-2-Yl Carbamate Derivatives as Magl Inhibitors
Heterocyclic Spiro Compounds as Magl Inhibitors
Anti-GDF15 Antibodies, Compositions and Methods of Use
Anti-GDF15 Antibodies, Compositions and Methods of Use
Neisseria Meningitidis Compositions and Methods Thereof
Neisseria Meningitidis Compositions and Methods Thereof
Neisseria Meningitidis Compositions and Methods Thereof
Neisseria Meningitidis Compositions and Methods Thereof
Tyrosine Prototrophy
Application:
16/492,793 →
Publication:
US US20200056190A1
N-Substituted-Dioxocyclobutenylamino-3-Hydroxy-Picolinamides Useful as CCR6 Inhibitors
N-Substituted-Dioxocyclobutenylamino-3-Hydroxy-Picolinamides Useful as CCR6 Inhibitors
Crystalline Form of Lorlatinib Free Base Hydrate
Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
Application:
17/312,185 →
Publication:
US US20220016229A1
Antibodies Specific for CD3 and Uses Thereof
Antibodies Specific for GUCY2C and Uses Thereof
Antibodies Specific for GUCY2C and Uses Thereof
IL-15 Variants and Uses Thereof
IL-12 Variants and Uses Thereof
Application:
63/353,241 →
Compositions and Methods for Eliciting an Immune Response Against Clostridium Difficile
Application:
16/647,124 →
Publication:
US US20200254081A1
Anti-Pd-1 Antibody Compositions
Application:
16/978,354 →
Publication:
US US20210002369A1
Crystalline 2-Amino-2-(Hydroxymethyl)Propane-1,3-Diol Salt of 4-(4-(1-Isopropyl-7-OXO-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypryridin-2-YL)benzoic acid
EZH2 Inhibitor Combination Therapies
Tetrahydroquinazoline Derivatives Useful as Anticancer Agents
Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents
Pyrrolo[2,3-D]Pyrimidine Tosylate Salt, Crystalline Form Thereof and Manufacturing Process and Intermediates Thereto
Antibody Purification
Application:
16/975,994 →
Publication:
US US20210017254A1
Escherichia Coli Compositions and Methods Thereof
Escherichia Coli Compositions and Methods Thereof
Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes)
Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes)
Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes)
Application:
17/190,924 →
Publication:
US US20210230196A1
Cyclin Dependent Kinase Inhibitors
Cyclin Dependent Kinase Inhibitors
Cyclin Dependent Kinase Inhibitors
Combination Treatments Of Cancer Comprising A TLR Agonist
Application:
17/415,348 →
Publication:
US US20220370606A1
Oral Solution Formulation
Chemical Compounds
Chemical Compounds
Dosage Regimen for TFPI Antagonists
Application:
17/283,801 →
Publication:
US US20210395391A1
A Novel PDE4 Inhibitor (R)-4-(5-(4-Methoxy-3-Propoxyphenyl)Pyridin-3-Yl)-1,2-Oxaborolan-2-Ol
Substituted 1,2-Oxaborolan-2-Ols as PDE4 Inhibitors
Boron Containing PDE4 Inhibitors
Application:
18/066,468 →
Publication:
US US20230148402A1
GLP-1 Receptor Agonists and Uses Thereof
GLP-1 Receptor Agonists and Uses Thereof
GLP-1 Receptor Agonists and Uses Thereof
GLP-1 Receptor Agonists and Uses Thereof
Application:
17/171,385 →
Publication:
US US20210163455A1
GLP-1 Receptor Agonists and Uses Thereof
Manufacturing Process and Intermediates for a Pyrrolo[2,3-D]Pyrimidine Compound and Use Thereof
Manufacturing Process and Intermediates for a Pyrrolo[2,3-D]Pyrimidine Compound and Use Thereof
Manufacturing Process and Intermediates for a Pyrrolo[2,3-D]Pyrimidine Compound and Use Thereof
Combinations For Treatment Of NASH/NAFLD And Related Diseases
Combinations For Treatment Of NASH/NAFLD And Related Diseases
Fusion Proteins and Uses Thereof
Application:
17/908,822 →
Publication:
US US20240209061A1
Pharmaceutical Compositions and Methods Comprising A Combination of a Benzoxazole Transthyretin Stabilizer and an Additional Therapeutic Agent
Novel Polymorphic Forms of a TGFBeta Inhibitor
Application:
16/716,696 →
Publication:
US US20200199104A1
Methods for purifying bacterial polysaccharides
Application:
17/431,462 →
Publication:
US US20220136020A1
Combination Therapies Using Cdk Inhibitors
Application:
17/613,304 →
Publication:
US US20230053328A9
Polymorph Form of a Monophosphate Hydrate Salt of a Known Tetrahydroisoquinoline Derivative
Application:
17/424,721 →
Publication:
US US20210387992A1
CDK2 Inhibitors
CDK2 Inhibitors
CDK2 Inhibitors
Azalactam Compounds as HPK1 Inhibitors
Pill Blister Pack
Patent:
889,279 →
Application:
29/679,760 →
Pill Blister Pack
Patent:
889,280 →
Application:
29/679,763 →
Cells with reduced inhibitor production and methods of use thereof
Application:
17/299,180 →
Publication:
US US20220073942A1
Human Cytomegalovirus Gb Polypeptide
Diacylglycerol Acyl Transferase 2 Inhibitor
Diacylglycerol Acyl Transferase 2 Inhibitor
Anti-E-Selectin Antibodies, Compositions and Methods of Use
Modulators of STING (Stimulator of Interferon Genes)
Anti-Proliferative Agents for Treating Pah
Blister Pack Pill Tray
Patent:
889,281 →
Application:
29/679,765 →
Blister Pack Pill Tray
Patent:
889,282 →
Application:
29/679,766 →
Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens, Kits Comprising the Same and Uses Thereof
Application:
17/601,949 →
Publication:
US US20220184199A1
Compositions and Methods for Eliciting an Immune Response Against Clostridium Difficile
Application:
17/594,107 →
Publication:
US US20220160859A1
Improvements to Wash Solutions for Protein a Chromatography in an Antibody Purification Process
Application:
17/620,148 →
Publication:
US US20220314142A1
Escherichia Coli Compositions and Methods Thereof
Application:
17/772,610 →
Publication:
US US20230000966A1
Combinations Comprising Benzodioxol as Glp-1R Agonists for Use in the Treatment of Nash/Nafld and Related Diseases
Real-Time Tracking and Management of Standard Workflows
Application:
17/607,341 →
Publication:
US US20220207454A1
Neisseria Meningitidis Compositions and Methods Thereof
Bckdk Inhibitors
Bckdk Inhibitors
Anti-Lymphotoxin Beta Receptor Antibodies and Methods of Use Thereof
Application:
63/340,753 →
Methods of Treating Duchenne Muscular Dystrophy Using Aav Mini-Dystrophin Gene Therapy
Application:
17/596,668 →
Publication:
US US20230241248A1
Toll-Like Receptor Agonists
Toll-Like Receptor Agonists
Improvements to Wash Solutions for Anion Exchange Chromatography in a Method of Purification of Recombinantly-Produced Rsv Proteins
Application:
18/006,800 →
Publication:
US US20230287041A1
5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases
Application:
17/619,912 →
Publication:
US US20220363673A1
Combination of an Anaplastic Lymphoma Kinase Inhibitor and a Cyclin Dependent Kinase Inhibitor
Stable Aqueous Anti-Tfpi Antibody Formulation
Application:
17/755,573 →
Publication:
US US20230035617A1
1-(((2S,3S,4S)-3-Ethyl-4-Fluoro-5-Oxopyrrolidin-2-Yl)Methoxy)-7-Methoxyisoquinoline-6-Carboxamide Combinations and Oral Dosage Forms
Application:
17/755,601 →
Publication:
US US20220378707A1
Compostions and Methods for Nucleic Acid Transfection Using Cationic Polymers and Stabilizers
Application:
17/756,951 →
Publication:
US US20230013253A1
Benzimidazole Derivative Compounds and Uses Thereof
Antibodies Specific for CD47, PD-L1, and Uses Thereof
Cells Having Gene Duplications and Uses Thereof
PRMT5 Inhibitor for Use In A Method of Treating Psoriasis and Other Autoimmune Conditions
Application:
17/758,468 →
Publication:
US US20230025976A1
Once Daily Cancer Treatment Regimen with a PRMT5 Inhibitor
Application:
17/786,695 →
Publication:
US US20230043985A1
Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
Application:
18/004,943 →
Publication:
US US20240116937A1
Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride
Application:
18/004,965 →
Publication:
US US20230242539A1
Solid Forms of 2-((4-((S)-2-(5-Chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-amine Salt
Application:
17/782,478 →
Publication:
US US20230045419A1
Recombinant Vaccinia Virus
Application:
17/790,160 →
Publication:
US US20230201283A1
Pyrrolo[2,3-D]Pyrimidine Derivatives
Application:
17/997,091 →
Publication:
US US20230219963A1
Combinations for Treatment of NAFLD/NASH and Related Diseases
Escherichia Coli Compositions and Methods Thereof
Application:
17/180,959 →
Publication:
US US20210268095A1
Purification of Saccharides
Application:
17/799,992 →
Publication:
US US20230085173A1
Melanocortin 4 Receptor Antagonists and Uses Thereof
Methods for Antagonizing a Melanocortin 4 Receptor
Combinations of Diacylglycerol Acyltransferase 2 Inhibitors and Acetyl-Coa Carboxylase Inhibitor
Application:
17/904,554 →
Publication:
US US20230405002A1
Methods of Inhibiting SARS-CoV-2 Replication and Treating Corona Virus Disease 2019
Application:
17/905,686 →
Publication:
US US20230157998A1
Methods, Therapies and Uses for Treating Cancer
Application:
17/924,975 →
Publication:
US US20230192878A1
Therapeutic Antibodies and Their Uses
Azalactam Compounds as HPK1 Inhibitors
Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof
Application:
17/824,295 →
Publication:
US US20220387576A1
Anti-GUCY2C Antibodies and Uses Thereof
Application:
17/917,886 →
Publication:
US US20230146072A1
Treatment of Type 2 Diabetes or Obesity or Overweight with 2-[(4-{6-[(4-Cyano-2-Fluorobenzyl)Oxy]Pyridin-2-Yl}Piperidin-1-Yl)Methyl]-1-[(2S)-Oxetan-2-Ylmethyl]-1H-Benzimidazole-6-Carboxylic Acid or a Pharmaceutically Salt Thereof
Application:
17/906,651 →
Publication:
US US20230201185A1
Method of Treating COVID-19
Methods of Treating Coronavirus Disease 2019
Application:
17/907,707 →
Publication:
US US20230149407A1
Compounds and Method of Treating COVID-19
Compounds and Methods for the Treatment of COVID-19
Application:
17/221,676 →
Compounds and Methods for the Treatment of COVID-19
Aminopyrimidinyl Derivatives
Human Cytomegalovirus Gb Polypeptide
Method of Treatment of Inflammatory Bowel Disease Using Anti-TL1A Antibodies
Application:
18/002,368 →
Publication:
US US20230235070A1
Immunogenic Compositions Against Clostridioides (Clostridium) Difficile and Methods Thereof
Battery Module and Battery Pack Including the Same
Application:
18/022,555 →
Publication:
US US20230318060A1
Stable Topical Formulations of 1(R)-4-(5-(4-Methoxy-3-Propoxphenyl)Pyridin-3-YL)-1,2-OX-Aborolan-2-OL
Application:
18/042,054 →
Publication:
US US20230310472A1
Recombinant Vaccinia Virus
Application:
17/371,206 →
Publication:
US US20220033784A1
Combination Therapy
Application:
18/017,071 →
Publication:
US US20230321042A1
Antiviral Heteroaryl Ketone Derivatives
Nitrile-Containing Antiviral Compounds
Nitrile-Containing Antiviral Compounds
Nitrile-Containing Antiviral Compounds
Nitrile-Containing Antiviral Compounds
Application:
17/932,151 →
Publication:
US US20230120254A1
Methods of Protecting RNA
Application:
18/041,447 →
Publication:
US US20230340530A1
Escherichia Coli Compositions and Methods Thereof
Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof
Metabolites of GLP1R Agonists
Metabolites of GLP1R Agonists
Application:
17/546,228 →
Publication:
US US20220193063A1
Time to Resolution of Axitinib-Related Adverse Events
Application:
17/538,919 →
Publication:
US US20220168293A1
(AZA)Benzothiazolyl Substituted Pyrazole Compounds
Application:
17/533,592 →
Publication:
US US20220184041A1
E. Coli Fimh Mutants and Uses Thereof
Modulators of STING (Stimulator of Interferon Genes)
3,4-Dihydro-2,7-Naphthyridine-1,6(2H,7H)-Diones as Mek Inhibitors
3,4-Dihydro-2,7-Naphthyridine-1,6(2H,7H)-Diones as Mek Inhibitors
Immunogenic Composition Against Influenza
Application:
17/733,566 →
Publication:
US US20220362372A1
Rna Molecules
Application:
18/045,967 →
Publication:
US US20230233671A1
Acc Inhibitors
Application:
63/393,712 →
Bckdk Inhibitors and/or Degraders
Multispecific Antibodies and Uses Thereof
Application:
63/268,817 →
Multispecific Antibodies and Uses Thereof
Application:
63/483,162 →
Methods for Producing an Adjuvant
Application:
63/319,418 →
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
Application:
63/384,626 →
Combination of a Braf Inhibitor, an Egfr Inhibitor, and a Pd-1 Antagonist for the Treatment of Previously Untreated Braf V600E-Mutant, Msi-H/Dmmr Colorectal Cancer
Application:
63/345,815 →
Novel SIK Inhibitors
Application:
63/376,480 →
Compositions and Methods for Eliciting an Immune Response Protective Against Lyme Disease
Application:
63/334,271 →
Compositions and Methods for Eliciting an Immune Response Protective Against Lyme Disease
Application:
63/357,398 →
Compositions and Methods for Eliciting an Immune Response Protective Against Lyme Disease
Application:
63/429,483 →
Anti-TL1A Antibodies and Methods of Use Thereof
Application:
63/364,559 →
Anti-TL1A Antibodies and Methods of Use Thereof
Application:
63/371,697 →
Pneumococcal Conjugate Vaccine Formulations
Application:
63/385,686 →
Anti-TNFR2 Antibodies and Methods of Use Thereof
Application:
63/365,371 →
Self-Amplifying Rna Encoding an Influenza Virus Antigen
Application:
63/359,857 →
Self-Amplifying Rna Encoding an Influenza Virus Antigen
Application:
63/431,462 →
Self-Amplifying Rna Encoding an Influenza Virus Antigen
Application:
63/484,745 →
Combination Therapy Comprising SIRP Alpha Fusion Protein and Anti-CD19 Antibody for Treatment of Cancer
Application:
63/351,117 →
Anti- IL27R Antibodies and Methods of Use Thereof
Application:
63/370,306 →
4-((6-(2,2-Difluoroethyl)-8-(2-Hydroxy-2-Methylcyclopentyl)-7-Oxo-7,8-Dihydropyrido[2,3-D]Pyrimidin-2-Yl)Amino)Piperidine-1-Sulfonamide for the Treatment of Cancer
Application:
63/379,924 →
Sirp alpha fusion protein and anti-CD38 antibody combination therapies
Application:
63/371,801 →
Rna Molecules
Application:
63/381,238 →
HSD17B13 Inhibitors and/or Degraders
Application:
63/378,807 →
Compounds for the Activation of Ampk
Application:
63/379,985 →
Immunogenic Compositions and Uses Thereof
Application:
63/431,743 →
Immunogenic Compositions and Uses Thereof
Application:
63/480,099 →
Immunogenic Compositions and Uses Thereof
Application:
63/484,746 →
Immunogenic Compositions and Methods for Elicitig an Immune Response Against Clostridioides (Clostridium) Difficile
Application:
63/387,100 →
New papain-like protease (PLpro) inhibitors
Application:
63/386,748 →
HSD17B13 Inhibitors and/or Degraders
Application:
63/387,759 →
Vaccines Against Respiratory Diseases
Application:
63/480,504 →
Related Assignments
(11)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jul 19, 2004
From: CUI, JINGRONG JEAN; BHUMRALKAR, DILIP; BOTROUS, IRINY; CHU, JI YU
To: SUGEN, INC.
Reel/Frame 014867/0434 →
Assignment of Assignor's Interest
Jan 7, 2005
From: MCHARDY, STANTON; LOWE, JOHN A.
To: PFIZER, INC.; PFIZER PRODUCTS, INC.
Reel/Frame 016148/0274 →
Assignment of Assignor's Interest
Sep 3, 2010
From: DEBELAK, HARALD; UHLMANN, EUGEN; JURK, MARION
To: COLEY PHARMACEUTICAL GMBH
Reel/Frame 024937/0046 →
Assignment of Assignor's Interest
Jun 1, 2011
From: SUGEN, INC.
To: PFIZER INC.
Reel/Frame 026373/0485 →
Assignment of Assignor's Interest
Jun 3, 2013
From: CUI, JINGRONG JEAN; FUNK, LEE ANDREW; JIA, LEI; KUNG, PEI-PEI
To: AGOURON PHARMACEUTICALS, INC.
Reel/Frame 030536/0193 →
Assignment of Assignor's Interest
Jun 4, 2013
From: AGOURON PHARMACEUTICALS, INC.
To: PFIZER INC.
Reel/Frame 030542/0832 →
Assignment of Assignor's Interest
Dec 16, 2020
From: COLEY PHARMACEUTICAL GMBH
To: PFIZER INC.
Reel/Frame 054662/0540 →
Assignment of Assignor's Interest
Dec 16, 2020
From: COLEY PHARMACEUTICAL GMBH
To: PFIZER INC.
Reel/Frame 054663/0356 →
Assignment of Assignor's Interest
Dec 16, 2020
From: DEBELAK, HARALD; UHLMANN, EUGEN; JURK, MARION
To: COLEY PHARMACEUTICAL GMBH
Reel/Frame 054663/0207 →
Assignment of Assignor's Interest
Dec 16, 2020
From: COLEY PHARMACEUTICAL GMBH
To: PFIZER INC.
Reel/Frame 054662/0923 →
Assignment of Assignor's Interest
Dec 16, 2020
From: DEBELAK, HARALD; UHLMANN, EUGEN; JURK, MARION
To: COLEY PHARMACEUTICAL GMBH
Reel/Frame 054662/0759 →